The incidence of intrathoracic tumours in Manchester, 1868-1926
Keywords:
malignant mesothelioma, history of medicineAbstract
Dr J. B. Duguid published a paper in 1927 entitled "The incidence of intrathoracic tumours in Manchester”. It was based on autopsies conducted at the Manchester Royal Infirmary between 1868 and 1926. While the majority of intrathoracic tumours had been diagnosed as bronchogenic carcinomas, there remained a small number affecting the pleura about which there had been uncertainty. Lancashire had been the cradle of Britain’s asbestos industry: Turner Brothers Asbestos had converted a cotton mill to asbestos in Rochdale in 1880, and had built another factory in Manchester in 1913, so that there would have been time enough for the development of asbestos associated malignancies. When in 1991 hindsight prompted a review of the Manchester clinical and autopsy materials, it was discovered that they had all been disposed of recently. The published descriptions of histopathological appearances in the uncertain cases were reviewed and it was concluded that, while it was impossible categorically to identify these lesions as mesothelial in phenotype, the anatomical site and the description offered the possibility. It is a matter of conjecture whether the identification of malignant mesothelioma in association with exposure to asbestos in 1926, would have prompted effective action to avert a major international public health disaster.
Downloads
Published
Issue
Section
License
OPEN ACCESS
All the articles of the European Journal of Oncology and Environmental Health are published with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/). This means that the author(s) retain copyright, but the content is free to download, distribute and adapt for commercial or non-commercial purposes, given appropriate attribution to the original article.
The articles in the previous edition of the Journal (European Journal of Oncology) are made available online with open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0 http://creativecommons.org/licenses/by/4.0/).
Upon submission, author(s) grant the Journal the license to publish their original unpublished work within one year, and the non exclusive right to display, store, copy and reuse the content. The CC-BY Creative Commons attribution license enables anyone to use the publication freely, given appropriate attribution to the author(s) and citing the Journal as the original publisher. The CC-BY Creative Commons attribution license does not apply to third-party materials that display a copyright notice to prohibit copying. Unless the third-party content is also subject to a CC-BY Creative Commons attribution license, or an equally permissive license, the author(s) must comply with any third-party copyright notices.